Robin Shane Readnour serves as Executive at AN2 Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Robin Shane Readnour has executed 10 insider transactions totaling $2.4M, demonstrating a bullish approach to their equity position. Their most recent transaction on Jan 12, 2024 involved selling 719 shares valued at $15.8K.
Robin Shane Readnour currently holds 485,073 shares of AN2 Therapeutics, Inc. (ANTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Robin Shane Readnour has been a net buyer of ANTX stock. They have purchased $2.3M and sold $111.7K worth of shares.
Robin Shane Readnour's most recent insider trade was on Jan 12, 2024, when they sold 719 shares at $21.91 per share.
Get notified when new Form 4 filings are submitted
| $21.92 |
| Planned |
| Jan 10, 2024 | ANTX | $39.5K | Sale | 1,800 | $21.92 | Planned |
| Jan 10, 2024 | ANTX | $41.0K | Sale | 1,869 | $21.93 | Planned |
| Mar 29, 2022 | ANTX | $1.2M | Purchase | 82,618 | $15.00 | Discretionary |
| Mar 29, 2022 | ANTX | $1.1M | Purchase | 70,716 | $15.00 | Discretionary |
| Mar 29, 2022 | ANTX | $0 | Conversion | 71,839 | $N/A | Discretionary |
| Mar 29, 2022 | ANTX | $0 | Conversion | 61,491 | $N/A | Discretionary |
| Mar 29, 2022 | ANTX | $0 | Conversion | 333,135 | $N/A | Discretionary |
| Mar 29, 2022 | ANTX | $0 | Conversion | 285,156 | $N/A | Discretionary |